ACTRN12612000977875招募中未知
Multi-country, cross sectional study to determine patient specific and General beliefs towards medication and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID)
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Female/male
- •18 years or over
- •Patients with Immune Mediated Inflammatory Disorders as diagnosed by a rheumatologist, gastroenterologist or dermatologist.
- •On current treatment with systemic either conventional and/or biologic immuno-modulating and/or disease-modifying drugs.
排除标准
- •Not applicable
研究者
相似试验
进行中（未招募）
不适用
This is a study to evaluate a radioactive agent that helps to detect signs ofchanges in the brain, indicating reduced brain function in thinking.Alzheimer's DiseaseEUCTR2012-002595-13-ITAVID RADIOPHARMACEUTICALS, INC.600
进行中（未招募）
不适用
Epidemiologic study to assess the IGRA positivity in populations with a high TBburdeCTRI/2023/01/048867Bill & Melinda Gates Medical Research Institute (Gates MRI)
已完成
不适用
A RANDOMISED, DOUBLE-BLIND, MULTINATIONAL STUDY TO PREVENT MAJOR VASCULAR EVENTS WITH TICAGRELOR COMPARED TO ASPIRIN (ASA) IN PATIENTS WITH ACUTE ISCHAEMIC STROKE OR TIA[SOCRATES –ACUTE STROKE OR TRANSIENT ISCHAEMIC ATTACK TREATED WITH ASPIRIN OR TICAGRELOR AND PATIENT OUTCOMES]-I63I63PER-081-13ASTRAZENECA PERU S.A.,135
进行中（未招募）
不适用
Study to evaluate antibody persistence & immune memory in subjects vaccinated during adolescence with Twinrix™.EUCTR2008-006083-11-CZGlaxoSmithKline Biologicals241
进行中（未招募）
不适用
Study to compare the immunogenicity, safety and reactogenicity of SmithKline Beecham’s Twinrix administered following a 2 dose schedule (0, 6 months) to that of Twinrix Junior administered following a 3 dose schedule (0, 1, 6 months) in healthy volunteers aged 12-15 years.To protect healthy volunteers between the ages of 12 and 15 years against hepatitis A and hepatitis B viruses and to determine the optimal dose range and schedule of the combined hepatitis A / hepatitis B vaccine, with respect to immunogenicity, reactogenicity and safety in this age group.EUCTR2015-001517-27-Outside-EU/EEAGlaxoSmithKline Biologicals300